[参考文献]
[1]LAMBACK E B, RESENDE F S, LENZI T C. Eosinophilic fasciitis[J]. An Bras Dermatol, 2016,91(5 suppl 1):57-59.
[2]YANO H, KINJO M. Eosinophilic fasciitis[J]. JAMA Dermatol, 2020,156(5):582.
[3]KREUTER A, KRIEG T, WORM M, et al. German guidelines for the diagnosis and therapy of localized scleroderma[J]. J Dtsch Dermatol Ges, 2016,14(2):199-216.
[4]MERTENS J S, SEYGER M M B, THURLINGS R M, et al. Morphea and eosinophilic fasciitis: an update[J]. Am J Clin Dermatol, 2017,18(4):491-512.
[5]张雅静, 岳伟. 皮肌炎诊断与治疗进展[J]. 中国现代神经疾病杂志, 2022,22(6):533-541.
[6]张春梅, 江翔, 蔡艳艳, 等. 硬肿病1例[J]. 临床皮肤科杂志, 2018,47(12):805-806.
[7]VARGA J, UITTO J, JIMENEZ S A. The cause and pathogenesis of the eosinophilia-myalgia syndrome[J]. Ann Intern Med, 1992,116(2):140-147.
[8]PINAL-FERNANDEZ I, SELVA-O′CALLAGHAN A, GRAU J M. Diagnosis and classification of eosinophilic fasciitis[J]. Autoimmun Rev, 2014,13(4-5):379-382.
[9]JINNIN M, YAMAMOTO T, ASANO Y, et al. Diagnostic criteria, severity classification and guidelines of eosinophilic fasciitis[J]. J Dermatol, 2018, 45(8):881-890.
[10]IHN H. Eosinophilic fasciitis: from pathophysiology to treatment[J]. Allergol Int, 2019,68(4):437-439.
[11]VILCHEZ-OYA F, SANCHEZ-SCHMIDT J M, AGUSTI A, et al. The use of tocilizumab in the treatment of refractory eosinophilic fasciitis: a case-based review[J]. Clin Rheumatol, 2020,39(5):1693-1698.
[12]KOUGKAS N, BERTSIAS G, PAPALOPOULOS I, et al. Rituximab for refractory eosinophilic fasciitis: a case series with long-term follow-up and literature review[J].Rheumatol Int, 2021,41(10):1833-1837.
[13]CAO X Y, ZHAO J L, HOU Y, et al. Janus kinase inhibitor tofacitinib is a potential therapeutic option for refractory eosinophilic fasciitis[J]. Clin Exp Rheumatol, 2020,38(3):567-568.
[14]SEHGAL R, ERNSTE F C, ECKLOFF S. Successful treatment with baricitinib in a patient with refractory eosinophilic fasciitis[J]. J Rheumatol, 2021,48(6):948-949.
[15]VIALL** J F, TAUPIN J L, RANCHIN V, et al. Analysis of leukemia inhibitory factor, type 1 and type 2 cytokine production in patients with eosinophilic fasciitis[J]. J Rheumatol, 2001,28(1):75-80.
[16]XIN P, XU X J, DENG C J, et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases[J]. Int Immunopharmacol, 2020,80:106210.
[17]ZHANG Y, LIANG R F, CHEN C W, et al. JAK1-dependent transphosphorylation of JAK2 limits the anti-fibrotic effects of selective JAK2 inhibitors on long-term treatment[J]. Ann Rheum Dis, 2017,76(8):1467-1475.